Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cardiology"
DOI: 10.1002/clc.22649
Abstract: Little is known about the comparative effectiveness and safety of non–vitamin K antagonist oral anticoagulants (NOAC) compared to warfarin in Chinese atrial fibrillation (AF) patients. Our aim was to compare the ischemic stroke risk reduction… read more here.
Keywords: atrial fibrillation; fibrillation; warfarin; safety ... See more keywords
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2021.11.008
Abstract: BACKGROUND The aim of the study was to compare the real-world effectiveness and safety in atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants (OACs) (apixaban, dabigatran, rivaroxaban, and vitamin K antagonists [VKA])… read more here.
Keywords: apixaban dabigatran; rivaroxaban; edoxaban versus; study ... See more keywords
Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis research"
DOI: 10.1016/j.thromres.2017.09.001
Abstract: Dabigatran etexilate, rivaroxaban and apixaban (DOACs) are widely used and measurement of their concentration is desirable in certain clinical situations. Target-specific assays are available but limited information exists on their performance especially in their ability… read more here.
Keywords: multicenter; dabigatran rivaroxaban; target specific; rivaroxaban apixaban ... See more keywords
Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.0401
Abstract: Vitamin K antagonists (VKA) and non-VKA oral anticoagulants (NOACs) are used to prevent thromboembolic conditions in patients with atrial fibrillation (AF). Unlike VKA, NOACs have fixed dosage schemes, do not require regular laboratory tests, and… read more here.
Keywords: rivaroxaban; vka; major bleeding; study ... See more keywords
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Internal Medicine"
DOI: 10.1111/joim.12683
Abstract: Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are lacking in patients with atrial fibrillation (AF). read more here.
Keywords: atrial fibrillation; standard reduced; rivaroxaban apixaban; doses dabigatran ... See more keywords
Indirect comparison of novel Oral anticoagulants among Asians with non-Valvular atrial fibrillation in the real world setting: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "BMC Cardiovascular Disorders"
DOI: 10.1186/s12872-019-1165-5
Abstract: BackgroundThe development of novel oral anticoagulants (NOACs) has changed the landscape of non-valvular atrial fibrillation (NVAF) management. In this study, the effectiveness and the safety of several NOACs were evaluated in a real-world setting among… read more here.
Keywords: real world; oral anticoagulants; non valvular; novel oral ... See more keywords